QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF) All Versions of this Article: 10/1/88    most recent 15228517-2007-044v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Google Scholar Articles by Stelzer, K. J. Articles by Spence, A. M. Search for Related Content PubMed PubMed Citation

Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme

Celilo Radiation Therapy, Mid-Columbia Medical Center (K.J.S.), The Dalles, OR; Department of Radiation Oncology (K.J.S., J.G.D., G.E.L.), Department of Nuclear Medicine (D.A.M., K.A.K.), Department of Neurological Surgery (J.G.D., D.L.S.), and Department of Neurology (A.M.S.), University of Washington Cancer Center, Seattle, WA; USA

Address correspondence to James G. Douglas, University of Washington Medical Center, Department of Radiation Oncology, Box 356043, Seattle, WA 98195-6043, USA (drjay{at}u.washington.edu).

Glioblastoma multiforme (GBM) continues to be a difficult therapeutic challenge. Our study was conducted to determine whether improved survival and tumor control could be achieved with modern delivery of fast neutron radiation using three-dimensional treatment planning. Ten patients were enrolled. Eligibility criteria included pathologic diagnosis of GBM, age 18 years, and KPS 60. Patients underwent MRI and ¹⁸F-fluorodeoxyglucose PET (FDG PET) as part of initial three-dimensional treatment planning. Sequential targets were treated with noncoplanar fields to a total dose of 18 Gy in 16 fractions over 4 weeks. Median and 1-year overall survival were 55 weeks and 60%, respectively. One patient remains alive at last follow-up 255 weeks after diagnosis. Median progression-free survival was 16 weeks, and all patients had tumor progression by 39 weeks. Treatment was clinically well tolerated, but evidence of mild to moderate gliosis and microvascular sclerosis consistent with radiation injury was observed at autopsy in specimens taken from regions of contralateral brain that received approximately 6-10 Gy. Fast neutron radiation using modern imaging, treatment planning, and beam delivery was feasible to a total dose of 18 Gy, but tumor control probability was poor in comparison to that predicted from a dose-response model based on older studies. Steep dose-response curves for both tumor control and neurotoxicity continue to present a challenge to establishing a therapeutic window for fast neutron radiation in GBM, even with modern techniques.

Key Words: FDG PET • glioblastoma multiforme • neutron radiotherapy

This article has been cited by other articles:

				A. M. Spence, M. Muzi, K. R. Swanson, F. O'Sullivan, J. K. Rockhill, J. G. Rajendran, T. C.H. Adamsen, J. M. Link, P. E. Swanson, K. J. Yagle, et al. Regional Hypoxia in Glioblastoma Multiforme Quantified with [18F]Fluoromisonidazole Positron Emission Tomography before Radiotherapy: Correlation with Time to Progression and Survival Clin. Cancer Res., May 1, 2008; 14(9): 2623 - 2630. [Abstract] [Full Text] [PDF]